Amneal Pharmaceuticals (NASDAQ:AMRX) Issues Q1 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.270-0.270 for the period, compared to the consensus EPS estimate of 0.160. The company issued revenue guidance of $723.0 million-$723.0 million, compared to the consensus revenue estimate of $715.0 million. Amneal Pharmaceuticals also updated its FY 2026 guidance to 0.950-1.050 EPS.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Truist Financial lifted their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. UBS Group started coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price on the stock. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $15.00.

Amneal Pharmaceuticals Trading Down 1.5%

NASDAQ:AMRX opened at $12.82 on Thursday. The stock has a market capitalization of $4.03 billion, a PE ratio of 55.74 and a beta of 1.32. Amneal Pharmaceuticals has a 1-year low of $7.02 and a 1-year high of $15.42. The firm has a fifty day simple moving average of $13.13 and a 200 day simple moving average of $12.53.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.11. Amneal Pharmaceuticals had a net margin of 2.39% and a negative return on equity of 228.24%. The firm had revenue of $723.00 million during the quarter, compared to analysts’ expectations of $709.79 million. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. On average, equities analysts predict that Amneal Pharmaceuticals will post 0.91 earnings per share for the current fiscal year.

Trending Headlines about Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat estimates: Amneal reported ~ $0.26–$0.27 EPS (above consensus) and revenue ahead of expectations; management raised Q1 and raised/affirmed FY2026 standalone guidance, supporting upside to 2026 revenue and EPS targets. Amneal Q1 Earnings Beat (Zacks)
• Positive Sentiment: Acquisition to expand biosimilars: Amneal agreed to acquire Kashiv BioSciences in a cash-and-stock deal worth up to $1.1B to build a fully integrated biosimilars platform and target a large biologics loss‑of‑exclusivity opportunity, which should diversify higher‑margin/complex product exposure over time. Amneal to buy Kashiv (Reuters)
• Neutral Sentiment: Management detail and Q&A released: The Q1 2026 earnings call transcript provides additional color on product trends, integration plans for Kashiv, and near‑term margin dynamics — useful for assessing execution but not an immediate catalyst by itself. Q1 2026 Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Financial/structural risks: Amneal still shows thin net margins and a negative return on equity; the $1.1B deal (cash + stock) and existing leverage raise dilution and credit concerns for some investors, which could pressure the stock despite revenue upside. AMRX Profile & Financial Metrics (MarketBeat)

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AMRX. Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $26,000. Federated Hermes Inc. boosted its position in Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Comerica Bank raised its position in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the period. Transamerica Financial Advisors LLC grew its stake in Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after buying an additional 2,460 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in Amneal Pharmaceuticals in the 3rd quarter valued at about $42,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.